

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The effectiveness of agomelatine on the severity and numbers of migraine attacks in patients with migraine

Protocol summary

Study aim

To determine the effectiveness of agomelatine on the severity, number of attacks, and days of migraine headaches

Design

Parallel randomized controlled trial design Patients referred for migraine treatment, if they consent to enter the study, will be randomly assigned to one of the intervention or control groups. The groups are treated by agomelatine or placebo. The sample size in this study will be 50 people for each group. The prescribing physician and the data collector will not be aware of the allocation method, and only the principal investigator will label the drug and placebo as A and B. The addition of this study is 3

Settings and conduct

Ziyaian and Imam Hospital Neurology Clinic patients were sampled consecutively over several months Sampling among the eligible patients if they were satisfied

Participants/Inclusion and exclusion criteria

Patients with migraine headache between 18 and 60 years who refer to a hospital for treatment of migraine . Patients with migraine who have other chronic diseases such as cardiovascular or brain diseases are not included in the study

Intervention groups

Receiving agomelatine 25 mg daily by the intervention group Receiving placebo vitamin B1 with the same shape and design as the medicine of the intervention group in the amount of 25 mg

Main outcome variables

Severity of headache; Number of headache attacks; Midas; Number of days with headache

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230303057599N1**

Registration date: **2023-05-24, 1402/03/03**

Registration timing: **retrospective**

Last update: **2023-05-24, 1402/03/03**

Update count: **0**

Registration date

2023-05-24, 1402/03/03

Registrant information

Name

Mahdi Shafiee Sabet

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 7707 8738

Email address

mshafiees@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-09-06, 1400/06/15

Expected recruitment end date

2022-02-09, 1400/11/20

Actual recruitment start date

2021-09-23, 1400/07/01

Actual recruitment end date

2022-03-16, 1400/12/25

Trial completion date

empty

Scientific title

The effectiveness of agomelatine on the severity and numbers of migraine attacks in patients with migraine

Public title

effect of Agomelatin on the migraine

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Migraine without aura without the use of preventive medicine

Exclusion criteria:

Pregnant woman those taking certain medications

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **50**

Actual sample size reached: **49**

Randomization (investigator's opinion)

Randomized

Randomization description

based on random table For this random assignment method in order to create groups with the same number Half of the total number of people who are going to enter will be randomly selected from the table of random numbers. The random number between 0 and 4 get the word AB, and if it was between 5 and 9, BA is assigned to it, then according to the entry, people will be in one of the two groups - intervention or control. For example, for a sample size of 60 people, if 30 random numbers are as follows: 396147224160811382693361771706 According to the above contract: From left to right, equal to the number: 3, AB Equivalent to 9, BA Equivalent to 6, BA Equation 1: AB Equation 4: AB

Blinding (investigator's opinion)

Triple blinded

Blinding description

The Medications were made by the relevant company in the same shape and design and in the same size, and only the main researcher was aware of the type of Tablets. The neurologist who prescribed, as well as the data collector and the data analyst, were unaware of which intervention the patient had undergone.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Imam Khomeini Hospital; Tehran University of Medical Sciences

Street address

Keshavarz Boulevard

City

Tehran

Province

Tehran

Postal code

۱۴۱۹۷۳۳۱۴۱

Approval date

2021-09-01, 1400/06/10

Ethics committee reference number

IR.TUMS.IKHC.REC.1400.219

Health conditions studied

1

Description of health condition studied

Migraine

ICD-10 code

G43.0

ICD-10 code description

Migraine without aura [common migraine]

Primary outcomes

1

Description

Severity and number of headache attacks

Timepoint

Three months after the intervention

Method of measurement

Checklist and interview

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: This group receives agomelatine 25 mg daily in tablet form for three months

Category

Treatment - Drugs

2

Description

Control group: This group receives vitamin B1 tablets with the same shape and design and weight of 25 mg equivalent to agomelatine for three months

Category

Placebo

+98 21 81631

Recruitment centers

1

Recruitment center

Name of recruitment center

Neurology Clinic of Imam Khomeini Hospital

Full name of responsible person

Shafiee Sabet Mahdi

Street address

Keshavarz Boulevard

City

Tehran

Province

Tehran

Postal code

۱۴۱۹۷۳۳۱۴۱

Phone

+98 21 6693 9010

Email

mshafiees@sina.tums.ac.ir

2

Recruitment center

Name of recruitment center

Ziaian Hospital

Full name of responsible person

Shafiee Sabet Mahdi

Street address

Ghazvin St.

City

Tehran

Province

Tehran

Postal code

1366736511

Phone

+98 21 5517 6813

Email

mshafiees@sina.tums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Akbar Fotoohi

Street address

Keshavarz Boulevard

City

Tehran

Province

Tehran

Postal code

1417653761

Phone

Email

mshafiees@sina.tums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Shafiee Sabet Mahdi

Position

Faculty Member

Latest degree

Specialist

Other areas of specialty/work

Neurology

Street address

Aboozar St

City

Tehran

Province

Tehran

Postal code

1366736511

Phone

+98 21 5575 1333

Email

mshafiees@sina.tums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Shafiee sabet Mahdi

Position

Faculty Member

Latest degree

Specialist

Other areas of specialty/work

Neurology

Street address

Aboozar St.

City

Tehran

Province

Tehran

Postal code

1366736511

Phone

+98 21 5517 6810

Email

mshafiees@sina.tums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

shafiee sabet mahdi

Position

Faculty Member

Latest degree

Specialist

Other areas of specialty/work

Neurology

Street address

Aboozar st.

City

Tehran

Province

Tehran

Postal code

1366736511

Phone

+98 21 5575 1333

Email

mshafiees@sina.tums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Not applicable